<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83353</article-id><article-id pub-id-type="doi">10.7554/eLife.83353</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-209324"><name><surname>Ge</surname><given-names>Mengyuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293997"><name><surname>Molina</surname><given-names>Judith</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287342"><name><surname>Kim</surname><given-names>Jin Ju</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293998"><name><surname>Mallela</surname><given-names>Shamroop Kumar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293999"><name><surname>Ahmad</surname><given-names>Anis</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294001"><name><surname>Varona Santos</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294002"><name><surname>Al-Ali</surname><given-names>Hassan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294000"><name><surname>Mitrofanova</surname><given-names>Alla</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294004"><name><surname>Sharma</surname><given-names>Kumar</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-294005"><name><surname>Fontanesi</surname><given-names>Flavia</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294003"><name><surname>Merscher</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-230249"><name><surname>Fornoni</surname><given-names>Alessia</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1313-7773</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><institution content-type="dept">Department of Medicine</institution>, <institution>University of Miami</institution>, <addr-line><named-content content-type="city">Miami</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Radiation Oncology</institution>, <institution>University of Miami</institution>, <addr-line><named-content content-type="city">Miami</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Center for Precision Medicine</institution>, <institution>The University of Texas Health Science Center at San Antonio</institution>, <addr-line><named-content content-type="city">San Antonio</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Biochemistry and Molecular Biology</institution>, <institution>University of Miami</institution>, <addr-line><named-content content-type="city">Miami</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-246038"><name><surname>Daehn</surname><given-names>Ilse S</given-names></name><role>Reviewing editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>AFornoni@med.miami.edu</email> (AF);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>02</day><month>05</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e83353</elocation-id><history><date date-type="received"><day>08</day><month>09</month><year>2022</year></date><date date-type="accepted"><day>26</day><month>04</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Ge et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Ge et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83353-v1.pdf"/><abstract><p>Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are anti-hyperglycemic agents that prevent glucose reabsorption in proximal tubular cells. SGLT2i improves renal outcomes in both diabetic and non-diabetic patients, indicating it may have beneficial effects beyond glycemic control. Here, we demonstrate that SGLT2i affects energy metabolism and podocyte lipotoxicity in experimental Alport syndrome (AS). <italic>In vitro</italic>, we found that SGLT2 protein was expressed in human and mouse podocytes to a similar extent of tubular cells. Newly established immortalized podocytes from Col4a3 knockout mice (AS podocytes) accumulate lipid droplets along with increased apoptosis when compared to wildtype podocytes. Treatment with SGLT2i empagliflozin reduces lipid droplet accumulation and apoptosis in AS podocytes. Empagliflozin inhibits the utilization of glucose/pyruvate as a metabolic substrate in AS podocytes but not in AS tubular cells. <italic>In vivo</italic>, we demonstrate that empagliflozin reduces albuminuria and prolongs the survival of AS mice. Empagliflozin-treated AS mice show decreased serum blood urea nitrogen and creatinine levels in association with reduced triglyceride and cholesterol ester content in kidney cortices when compared to AS mice. Lipid accumulation in kidney cortices correlates with the decline in renal function. In summary, empagliflozin reduces podocyte lipotoxicity and improves kidney function in experimental AS in association with the energy substrates switch from glucose to fatty acids in podocytes.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01DK117599,R01DK104753,R01CA227493</award-id><principal-award-recipient><name><surname>Merscher</surname><given-names>Sandra</given-names></name><name><surname>Fornoni</surname><given-names>Alessia</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100019337</institution-id><institution>Miami Clinical and Translational Science Institute, University of Miami</institution></institution-wrap></funding-source><award-id>U54DK083912,UM1DK100846,U01DK116101,UL1TR000460</award-id><principal-award-recipient><name><surname>Fornoni</surname><given-names>Alessia</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000183</institution-id><institution>Army Research Office</institution></institution-wrap></funding-source><award-id>W911NF-21-1-0359</award-id><principal-award-recipient><name><surname>Fontanesi</surname><given-names>Flavia</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Kumar Sharma, is founder of SygnaMap..</p></fn><fn fn-type="conflict" id="conf3"><p>Sandra Merscher, is an inventor on pending (PCT/US2019/032215; US 17/057,247; PCT/US2019/041730; PCT/US2013/036484; US 17/259,883; US17/259,883; JP501309/2021, EU19834217.2; CN-201980060078.3; CA2,930,119; CA3,012,773,CA2,852,904) or issued patents (US10,183,038 and US10,052,345) aimed at preventing and treating renal disease. They stand to gain royalties from their future commercialization. SM holds indirect equity interest in, and potential royalty from, ZyVersa Therapeutics, Inc. by virtue of assignment and licensure of a patent estate. SM is supported by Aurinia Pharmaceuticals Inc..</p></fn><fn fn-type="conflict" id="conf4"><p>Alessia Fornoni, is an inventor on pending (PCT/US2019/032215; US 17/057,247; PCT/US2019/041730; PCT/US2013/036484; US 17/259,883; US17/259,883; JP501309/2021, EU19834217.2; CN-201980060078.3; CA2,930,119; CA3,012,773,CA2,852,904) or issued patents (US10,183,038 and US10,052,345) aimed at preventing and treating renal disease. They stand to gain royalties from their future commercialization. AF is Vice-President of L&amp;F Health LLC and is a consultant for ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc has licensed worldwide rights to develop and commercialize hydroxypropyl-beta-cyclodextrin from L&amp;F Research for the treatment of kidney disease. AF also holds equities in Renal 3 River Corporation. AF and SM are supported by Aurinia Pharmaceuticals Inc..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All studies involving mice were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Miami. The University of Miami (UM) has an Animal Welfare Assurance on file with the Office of Laboratory Animal Welfare, NIH (A-3224-01, effective November 24, 2015). Additionally, UM is registered with the US Department of Agriculture Animal and Plant Health Inspection Service, effective December 2014, registration 58-R-007. As of October 22, 2013, the Council on Accreditation of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International) has continued UM's full accreditation.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file.</p></sec><supplementary-material><ext-link xlink:href="elife-83353-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>